This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2015
  • /
  • 04
  • /
  • Pabal (carbetocin) new formulation approved throug...
Drug news

Pabal (carbetocin) new formulation approved through EU Mutual Recognition Procedure for prevention of uterine atony and postpartum haemorrhage - Ferring

Read time: 1 mins
Last updated:14th Apr 2015
Published:14th Apr 2015
Source: Pharmawand

Ferring announced that its new room-temperature-stable formulation of Pabal (carbetocin) for intravenous (IV) administration has been approved through the EU Mutual Recognition Procedure. Pabal is a long-acting synthetic analogue of human oxytocin with a half-life of approximately 40 minutes and is indicated for the prevention of uterine atony following delivery of the infant by caesarean section under epidural or spinal anaesthesia. The new formulation of Pabal is the first long-acting, room-temperature-stable oxytocic agent to be approved for this condition.

Room-temperature-stable Pabal is expected to become available in Europe during the second quarter of 2015. Uterine atony, or lack of muscle tone in the uterus, is responsible for approximately 80% of postpartum haemorrhage (PPH) cases. PPH is defined as a bleed of 500 mL or more in vaginal deliveries and in excess of 1000 mL in abdominal deliveries. International and national guidelines agree that active management of the third stage of labour is a key factor in preventing PPH. This is often achieved with uterotonic agents like oxytocin, ergometrine, syntometrine and the other formulations of carbetocin, all of which require refrigeration from manufacture, through distribution, storage and eventual use.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.